CD137, a member of the tumor necrosis factor (TNF) receptor family, is a type 1 transmembrane protein, expressed on surfaces of leukocytes and non-immune cells. [5][6] Its alternative …

2024年1月4日 · Since its initial description 35 years ago as an inducible molecule expressed in cytotoxic and helper T cells, 4-1BB has emerged as a crucial receptor in T-cell-mediated …

Signaling via 4-1BB by anti-4-1BB activates various immune competent cells, leading to activation, cytokine induction, prevention of activation-induced cells death (AICD), upregulation …

Stimulation of 4-1BB, a surface receptor expressed on activated T cells amongst many other types of immune cells, activates various signaling pathways involved in the generation of a …

2018年1月4日 · Agonistic monoclonal antibodies targeting 4-1BB have been developed to harness 4-1BB signaling for cancer immunotherapy. Preclinical results in a variety of induced …

In this review, we discuss preclinical and clinical results for new 4–1BB agonists that have entered clinical studies. The clinical development of agonistic 4–1BB antibodies started in 2005 with …

4-1BB (CD137), a member of the TNF receptor superfamily, is an activation-induced T-cell costimulatory molecule. Signaling via 4-1BB upregulates survival genes, enhances cell …

4-1BB (CD137) is being thought of as an attractive target for immunotherapy of many human immune diseases based on encouraging results with 4-1BB agonistic antibody treatment in …

In this review, we briefly examine the role of 4-1BB in T-cell biology, explore its clinical applications, and discuss future prospects in the field of 4-1BB agonist immunotherapy.

On NK cells, 4-1BB signaling can increase antibody-dependent cell-mediated cytotoxicity. Agonistic monoclonal antibodies targeting 4-1BB have been developed to harness 4-1BB …